

singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line; [.]

with the proviso that the non-primate mammalian cell line is not BHK.

3. (twice amended) The method of Claim 1, wherein said cell line [expresses galactose α (1,3) galactosyl epitopes and is not treated to reduce such expression] is human serum-resistant.

20. (amended) Retroviral vector particles produced by the methods of any one of Claims 11, [12,] 16, 44 or [41] 45.

46. (amended) A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises

(a) introducing one or more packaging vectors into a human serum-resistant non-primate mammalian cell line, [wherein said cell line expresses galactose α (1,3) galactosyl epitopes and is not treated to reduce such expression, and] wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line.

48. (amended) The method of Claim 46, wherein said cell line exhibits [substantially] no specific hybridization to a Moloney-MLV retrovirus [*gag*, *pol*,] *gag-pol* or *env* probe[under stringent washing conditions].

In Claim 50, please delete "produced" and insert therefor --produced--

In Claim 51, at line 5, please delete "or" and insert therefor --of--

53. (amended) The method of Claim 51, wherein said cells exhibit [substantially] no specific hybridization to a Moloney-MLV retrovirus [*gag*, *pol*,] *gag-pol* or *env* probe[under stringent washing conditions].

58. (amended) The method of Claim 56 wherein said cell line exhibits [substantially] no specific hybridization to a Moloney-MLV retrovirus [*gag*, *pol*,] *gag-pol* or *env* probe[under stringent washing conditions].